Researchers are set to launch a groundbreaking clinical trial evaluating the efficacy of smoked medical marijuana in treating post-traumatic stress disorder (PTSD) among military veterans.
The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase 2 study of smoked cannabis in Veterans for the treatment of PTSD (MJP2) to proceed. Initially placed on partial clinical hold by the FDA in 2021, MJP2 is a randomized, placebo-controlled study of 320 Veterans suffering from moderate to severe PTSD who have previously used cannabis.
Funded by the Michigan Veteran Marijuana Research Grant Program, trial will investigate the effects of inhaling high-THC dried cannabis flower versus a placebo, allowing participants to self-titrate their dosage. MAPS noted the study reflects real-world consumption patterns, aiming to assess both the benefits and risks of cannabis use for PTSD treatment.
Continue reading